Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Type II Diabetes

Therapeutic area intelligence for Type II Diabetes with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
0
Companies
0

Companies

No related entities indexed yet.

Assets

No related entities indexed yet.

Recent signals(1)

ClinicalJune 25, 2026

Study on Duodenal pulsENDO for Type II Diabetes and Liver Disease Initiated

A clinical trial is underway to assess the efficacy and safety of the pulsENDO procedure in patients with suboptimally controlled Type II Diabetes Mellitus and steatotic liver disease.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Type II Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.